| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 18, 2017First-Ever Study on 2.0 mm DES, EuroPCR Late-Breaking Data Show Exceptional Deliverability and No Stent Thrombosis for the Resolute Onyx DES
DUBLIN and PARIS- May 18, 2017 - Medtronic plc (NYSE: MDT) today announced that the Resolute Onyx(TM) Drug-Eluting Stent (DES) met its primary endpoint of Target Lesion Failure (TLF) at one year...
-
May 1, 2017Engineered for Exceptional Deliverability, Advanced DES Technology Features Thinner Struts, Enhanced Visibility and the Broadest Size Matrix in the U.S.
DUBLIN – May 1, 2017 – Medtronic plc (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the Resolute Onyx™ Drug-Eluting Stent (DES). The...
-
Feb 13, 2017Full Line of Innovative Transradial Products and Comprehensive Training Programs Reinforce Medtronic's Commitment to Optimizing the Treatment of Heart Disease
DUBLIN - Feb. 13, 2017 - Medtronic plc (NYSE: MDT) today announced that its market-leading coronary portfolio will now include the DxTerity Diagnostic Angiography Catheter line and several...
-
Oct 31, 2016Featured 'First Report' RevElution Trial at TCT Highlights the Potential Benefits of First-of-its-Kind Polymer-Free Technology with Controlled and Sustained Drug Delivery for Rapid Vessel Healing
DUBLIN and WASHINGTON, D.C. - Oct. 31, 2016 - Medtronic plc (NYSE: MDT) unveiled today the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the RevElution Trial at the...
-
Apr 3, 2016Medtronic Announces Early Data and Completes Enrollment in CE Mark Cohort in Drug-Filled Stent TrialRevElution Trial with Next-Gen Polymer-Free Stent Continues to Show Excellent Rapid Healing and Controlled Drug Delivery at ACC.16
DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) announced new clinical data today from one of the endpoints in the RevElution Trial for its novel, next-generation Drug-Filled Stent...